NCT02435121View on ClinicalTrials.gov

A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification

PHASE2CompletedINTERVENTIONAL

Enrollment

1

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions

Neoplasm Malignant

Interventions

DRUG

SAR125844

Pharmaceutical form:Concentrate for solution Route of administration: intravenous

Trial Locations (1)

B-2650

Investigational Site Number 056001, Edegem

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Sanofi

INDUSTRY